Dr. David L. Lacey M.D. serves as Independent Director of the Company. serves as Independent Director of the Company.D is Independent Director of the Company. Dr. Lacey currently serves as Scientific Advisor at Verdant Therapeutics Inc., a biotechnology company. Prior to that, Dr. Lacey held roles of increasing responsibility at Amgen from 1994 to 2011, including as Senior Vice President of Research. Dr. Lacey currently serves on the board of directors of argenx SE, a public biotechnology company. He also serves on the boards of directors of Nurix, Inc., a biotechnology company, and Inbiomotion SL, a biotechnology company. He previously served on the boards of directors or as an advisory board member to Bay Area Bioscience Association and AnaptysBio, Inc. Dr. Lacey previously served as Assistant Professor of Pathology at Jewish Hospital, Washington University Medical Center and was also a postgraduate research associate in the University of Colorado’s Department of Pathology. Dr. Lacey received a B.S. in Biology and an M.D. from the University of Colorado. Lacey is qualified to serve on our board of directors due to his extensive experience in biopharmaceutical development, as an advisor to biotechnology companies and his medical background.
As the Independent Director of Unity Biotechnology Inc, the total compensation of David Lacey at Unity Biotechnology Inc is $230,580. There are 9 executives at Unity Biotechnology Inc getting paid more, with Keith Leonard having the highest compensation of $3,270,820.
David Lacey is 67, he's been the Independent Director of Unity Biotechnology Inc since 2018. There are no older and 22 younger executives at Unity Biotechnology Inc.
David's mailing address filed with the SEC is C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD, CA, 94545.
Over the last 7 years, insiders at Unity Biotechnology Inc have traded over $9,012,473 worth of Unity Biotechnology Inc stock and bought 3,200 units worth $28,480 . The most active insiders traders include Kristina Burow, Robert Nelsen und Nathaniel E David. On average, Unity Biotechnology Inc executives and independent directors trade stock every 54 days with the average trade being worth of $65,316. The most recent stock trade was executed by Alexander Hieu Nguyen on 2 August 2024, trading 154 units of UBX stock currently worth $236.
unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.
Unity Biotechnology Inc executives and other stock owners filed with the SEC include: